Angiotensin converting enzyme inhibitors and vascular protection in hypertension

Journal of Cardiovascular Pharmacology

Volumn 34, Issue SUPPL. 1, 1999, Pages

  Ruschitzka, Frank ^a   Noll, Georg ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ACE inhibitor; CardiOvascular disease; Endothelin; Endothelium; Hypertension

Indexed keywords

27 O 3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATRASENTAN; BMS 193884; BOSENTAN; BRADYKININ; BRADYKININ B2 RECEPTOR; BSM 20794; CAPTOPRIL; CLAZOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMD 94246; ENALAPRIL; ENDOTHELIN; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; L 743929; LISINOPRIL; LOSARTAN; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; NITRIC OXIDE; PD 159433; PD 56707; PROSTACYCLIN; SITAXSENTAN; T 0115; TAK 044; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; EXPERIMENTAL MODEL; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0032888436     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908001-00002     Document Type: Conference Paper

References (101)

1. Lüscher TF, Vanhoutte PM. The endothelium: modulator of cardiovascular function. CRC Press. Boca Raton; 1990. pp. 1-215.
2. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effect of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-662.
3. Johnstone MT, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelial-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993;88:2510-2516.
4. Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995;92:1094-1100.
5. Chowienczyk PJ, Watts GF, Cockroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430-1432.
6. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-1253.
7. Taddei S, Virdis A, Ghiadoni L, et al. Menopause is associated with endothelial dysfunction in women. Hypertension 1996;28: 576-582.
8. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilatation to acetylcholine in primary and secondary forms of hypertension. Hypertension 1993;21:929-933.
9. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-774.
10. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;299:373-376.
12. Rapoport RM, Draznin MB, Murad F. Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 1983;306:174-176.
13. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-646.
14. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
15. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-115.
16. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
17. de Nucci G, Thomas R, D'Orleans Juste P, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85: 9797-9800.
18. Lüscher TF, Seo BG, Bühler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993;21:752-757.
19. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
20. Hu RM, Levin ER, Pedram A, Frank HJL. Atrial natriuretic peptide inhibits the production and secretion of endothelin-1 from cultured endothelial cells: mediation through the C receptor. J Biol Chem 1992;267:17384-17389.
21. Emoto N, Xie J, Yanagisawa M. Intracellular and cell-surface isoforms of endothelin converting enzyme-1 generated by tissue specific alternative splicing [abstract]. Circulation 1996;94:3433.
22. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 1994;78:473-485.
23. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994;269:18275-18278.
24. Barnes K, Brown C, Turner AJ. Endothelin-converting enzyme. Ultrastructural localization and its recycling from the cell surface. Hypertension 1998;31:3-9.
25. Valdenaire O, Rohrbacher E, Mattei MG. Organization of the gene encoding the human endothelin converting enzyme (ECE-1). J Biol Chem 1995;270:29794-29798.
26. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
27. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-732.
28. Kiowski W, Lüscher TF, Linder L, Bühler FR. Endothelin-1 induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991:83:469-475.
29. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation 1994;89:2212-2218.
30. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; ii:997-1000.
31. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997;96:1593-1597.
32. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986;8:344-348.
33. Tschudi M, Richard V, Bühler FR, Lüscher TF. Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol 1991;260:H13-H20.
34. Küng CF, Lüscher TF. Different mechanism of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995;25:194-200.
35. Joannides R, Richard V, Haefeli WE, Linder L, Lüscher TF, Thuillez C. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans. Hypertension 1995; 26:327-331.
36. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353.
37. Hishikawa K, Lüscher TF. Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation 1997;96: 3610-3616.
38. Noll G, Lang MG, Tschudi MR, Ganten D, Lüscher TF. Endothelial vasoconstrictor prostanoids modulate contractions to acetylcholine and ANG II in Ren-2 rats. Am J Physiol 1997;272: H493-H500.
39. Diederich D, Yang ZH, Bühler FR, Lüscher TF. Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol 1990;258:H445-H551.
40. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
41. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-2551.
42. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-10048.
43. Cosentino F, Patton S, d'Uscio LV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998;101:1530-1537.
44. Lüscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension 1987;9 (suppl III):193-197.
45. Li JS, Lariviere R, Schiffrin EL. Effect of a non-selective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994;24:183-188.
46. Takada K, Matsumura Y, Dohmen S. Mitsutomi N, Takaoka M, Morimoto S. Endothelin-1 secretion from cultured vascular endothelial cells of DOCA-salt hypertensive rats. Life Sci 1996;59: L11-L116.
47. Clozel M, Breu V, Burri K, et al. Pathophysiologic role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365:759-761.
48. Li JS, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995;25:495-500.
49. Stasch JP, Hirth Dietrich C, Frobel K, Wegner M. Prolonged endothelin blockade reduces hypertension and cardiac hypertrophy in SHR-SP. J Cardiovasc Pharmacol 1995;26:S436-S438.
50. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31:499-504.
51. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996;27:H88-H93.
52. Ruschitzka F, Shaw S, Gygi D, Noll G, Barton M, Lüscher TF. Endothelial dysfunction in acute renal failure. Role of circulating and tisue endothelin-1. J Am Soc Nephrol 1999;10:953-962.
53. Sventek P, Turgeon A, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in 1-kidney, one clip Goldblatt hypertensive rats but only in the late phase 3-kidney, one clip Goldblatt hypertension. J Hypertens 1996;14:57-64.
54. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension 1997;29:435-441.
55. Donckier JE, Massart PE, Hodiege D, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997; 96:1250-1256.
56. Moreau P, Takase H, Kung CF, Shaw S, Lüscher TF. Blood pressure and vascular effects of endothelin-blockade in chronic nitric oxide-deficient hypertension. Hypertension 1997;29:763-769.
57. Verma S, Bhanot S, McNeill JH. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am J Physiol 1995;269:H2017-H2021.
58. Niranjan V, Telemaque S, Dewit D, Gerard RD, Yanagisawa M. Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest 1996;98:2364-2372.
59. Hocher B, Liefeldt L, Thone Reineke C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996;28:196-201.
60. Kurihara Y, Kurihara H, Oda H, et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995;96:293-300.
61. Tschudi MR, Lüscher TF. Age and hypertension differently affect coronary contractions to endothelin-1, serotonin, and angiotensins. Circulation 1995;91:2415-2522.
62. Panza JA, Quyyumi AA, Brush JJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
63. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10:1025-1031.
64. Forte P, Copland M, Smith LM, Milne E, Sutherland J, Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 1997;349:837-842.
65. Cockcroft JR, Chowienczyk PJ, Benjamin N, Ritter JM. Preserved endothelium-dependent vasodilatation in patients with essential hypertension. N Engl J Med 1994;330:1036-1040.
66. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97: 2222-2229.
67. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol 1991;261:F1033-F1037.
68. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575.
69. Yokokawa K, Tahar T, Kohno M, et al. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 1991;114:213-215.
70. Kamoi K, Sudo N, Ishibashi M, Yamaji T, et al. Plasma endothelin-1 levels in patients with pregnancy-induced hypertension [letter]. N Engl J Med 1990;332:1486-1487.
71. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension [published erratum appears in Hypertension 1997;29:912]. Hypertension 1996;28:652-655.
72. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992;267:16066-16068.
73. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784-790.
74. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996;93:1860-1870.
75. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996;94:2077-2082.
76. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-854.
77. Kaasjager KA, Koomans HA, Rabelink TJ. Endothelin-1-induced vasopressor response in essential hypertension. Hypertension 1997;30:15-21.
78. Haynes WG, Moffat S, Webb DJ. An investigation of the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. Br J Pharmacol 1995;40:307-311.
79. Noll G, Wenzel RR, Schneider M, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation 1996;93:866-869.
80. Schiffrin EL, Deng LY, Sventek P, Day R. Enhanced expression of endothelin-1 gene in resistance arteries in sever human essential hypertension. J Hypertens 1997;15:57-63.
81. Dohi Y, Criscione L, Pfeiffer K, Lüscher TF. Angiotensin blockade or calcium antagonists improve endothelial dysfunction in hypertension: studies in perfused mesenteric resistance arteries. J Cardiovasc Pharmacol 1994;24:372-379.
82. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
83. Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina M, Lüscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol 1993;22:S17-S22.
84. Gainer JV Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
85. Takase H, Moreau P, Küng CF, Nava E, Lüscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Hypertension 1996;27:25-31.
86. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Anti hypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995;115:1377-1381.
87. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996;94:254-265.
88. Mimran A, Ribstein J, DuCailar G. Contrasting effect of antihypertensive treatment on the renal response to L-arginine. Hypertension. 1995;26:937-941.
89. Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension 1994;24:499-505.
90. Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension 1996;27:371-376.
91. Taddei S, Virdis A, Ghiadoni L, Mattel P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998;16:447-456.
92. Timmermanns PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5:221S-235S.
93. d'Uscio LV, Shaw S, Barton M, Lüscher TF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension 1998;31:1305-1310.
94. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contributions to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
95. Rodrigo E, Maeso R, Muno Garcia R, et al. Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J Hypertens 1997;15:613-618.
96. Baan J, Chang PC, Vermeij P, Pfaffendorf M1 van Zwieten PA. Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. J Hypertens 1998;16:1299-1305.
97. Donckier J, Stoleru L, Hayashida W, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995;92:106-113.
98. Richard V, Hogie M, Clozel M, Loffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995;91:771-775.
99. Wenzel RR, Noll G, Lüscher TF. Endothelin receptor antagonists inhibit endothelin in human sin microcirculation. Hypertension 1994;23:581-586.
100. Sutsch G, Fleisch M, Yan X-W, Binggeli C, Bianchetti MC, Kiowski W, Lüscher TF. Acute hemodynamic and renal effect of the endothelin-1 receptor antagonist TAK-044 in patients without heart failure. J Am Coll Cardiol 1997;29 (suppl A):444A.
101. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998;98:2235-2240.